Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win Read more
Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nod Read more
Regeneron ends eye disease trial for anti-CD3 antibody following safety review Read more
Navid Gholampour
Navid has over a decade of experience in Life Sciences recruitment. He partners with leaders to build patient-focused and innovative organisation
